Barclays Adjusts Price Target#
Barclays has raised its price target for Molina Healthcare Inc. shares from $133 to $161, while maintaining an Underweight rating on the stock. Currently, Molina's shares are trading at $174.70, which is already above the new target. Despite this, data suggests that the stock may still be undervalued, with a Fair Value estimated at $204.83.
Earnings Estimates and Valuation#
The increase in price target reflects a higher valuation multiple of 12 times the estimated earnings per share (EPS) for 2027, up from 11 times previously. Barclays has kept its earnings estimates for 2026 and 2027 unchanged, indicating confidence in the company's financial outlook.
Medicaid Business Stabilization#
One of the key reasons for the revised price target is the observed stabilization in Molina's Medicaid business. Barclays also noted positive trends in the company's underlying costs. Additionally, Molina's balance sheet shows more cash than debt, which enhances its financial flexibility in the competitive healthcare market.
Recent Earnings Performance#
In its recent earnings report for the first quarter of 2026, Molina exceeded analyst expectations with an adjusted EPS of $2.35, surpassing the forecast of $2.17. This represents an 8.29% surprise in EPS. However, the company did experience a slight revenue miss, reporting $10.8 billion against a forecast of $10.87 billion. Despite this, the strong EPS performance reflects positively on Molina's financial management, attracting the attention of investors and analysts alike.